Search Results

ASLAN Pharmaceuticals announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd., to establish a framework for a succession of research projects to explore the differentiation of eblasakimab’s mechanism of action versus biologic therapies for atopic dermatitis, dupilumab and lebrikizumab.

ASLAN Pharmaceuticals Ltd. announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares, each ADS representing twenty-five ordinary shares, at an offering price of $1.00 per ADS in a registered direct offering.

ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.

ASLAN Pharmaceuticals announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

ASLAN Pharmaceuticals Ltd. announced that it has begun to enroll patients in the US under an updated protocol in the ongoing TREK-DX trial, studying eblasakimab in dupilumab-experienced patients with moderate-to-severe atopic dermatitis.

ASLAN Pharmaceuticals Ltd. announced new positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of chronic obstructive pulmonary disease that provides further support for the potential of eblasakimab as a biologic therapy for COPD.

ASLAN Pharmaceuticals today announced its participation in upcoming conferences for January 2024.

ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an update on recent corporate activities.

ASLAN Pharmaceuticals announced that it received a letter on April 18, 2024 from The Nasdaq Stock Market informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5550 for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2.5 million.